Compounded semaglutide and tirzepatide: what TikTok gets wrong

What did @shoorahj actually say?

She's frustrated and confused, and honestly, that comes through clearly. The creator describes jumping between compound pharmacies, getting wildly inconsistent results, and seriously considering so-called "research peptides" because a creator friend has had success with them. She also claims that brand-name Mounjaro is batch-tested for quality while compound pharmacies "just don't have that ability." And she asks her followers to crowdsource pharmacy recommendations based on six months of consistent results.

She's not making a single bold claim here. This is more of a public venting session that contains several embedded assumptions worth pulling apart. Some of those assumptions are reasonably grounded. Others are not.

Does the science back this up?

Partly. The core frustration, that compounded GLP-1 medications vary in potency and effectiveness, is real and documented. The rest gets murkier fast.

The FDA has flagged compounded semaglutide and tirzepatide products repeatedly. In 2024, the agency issued warnings specifically about dosing errors and product quality concerns with compounded versions of these drugs. A 2023 analysis published in JAMA by Downing et al. found that the 503A compounding pharmacy oversight framework lacks the systematic batch-release testing requirements that apply to FDA-approved manufacturers. That supports her general instinct about quality control gaps.

However, her framing that brand-name Mounjaro is simply "batch tested and thrown away" if it fails is an oversimplification. Eli Lilly's manufacturing process involves current Good Manufacturing Practice (cGMP) compliance, which includes in-process testing, stability studies, and release criteria, not just a single batch test. The difference in oversight between compounded and brand-name products is real, but her description undersells how rigorous the brand-name side actually is.

What did they get wrong (or right)?

She got the quality inconsistency concern basically right. Research comparing 503A and 503B compounding pharmacies consistently shows that neither category is subject to the same mandatory pre-market efficacy or potency verification as FDA-approved drugs. She's experiencing something real.

What she got wrong is more serious. She floats the idea of using "research peptides" because a friend had success with them. She even acknowledges the "not for human consumption" label herself, then keeps the door open anyway. That label is not a technicality. Research peptides sold online are not manufactured under any regulatory standard for human use. Purity, concentration, and sterility are unverified. The FDA has explicitly warned consumers against injecting these compounds.

She also casually mentions AOD-9604 and BPC-157 as peptides she gets from a company called Valhalla and describes them as "top notch." AOD-9604 is not FDA-approved for any indication. BPC-157 has no approved human use. Describing these as effective treatments, even indirectly, is misleading to her 20,000 viewers.

Her crowdsourcing strategy, asking followers which pharmacy worked for them, is also a genuinely poor approach to a clinical question. Anecdote is not a quality control mechanism.

What should you actually know?

The inconsistency she's describing in compounded GLP-1 products is not random bad luck. It reflects structural gaps in how 503A pharmacies are regulated. Unlike 503B outsourcing facilities, 503A pharmacies operate under state pharmacy board oversight and are not required to meet FDA cGMP standards. Testing requirements vary by state and by pharmacy. That means two pharmacies can sell what looks like the same product, at the same dose, with meaningfully different actual potency.

If you're using compounded tirzepatide or semaglutide, the questions worth asking your provider include: Is this pharmacy 503A or 503B? Do they conduct third-party Certificate of Analysis testing on finished products? What's the base ingredient, tirzepatide base or a salt form like tirzepatide hydrochloride, and does that match what the prescriber intended?

Research peptides are a different category entirely and not a workaround. They are not a regulated alternative to compounded or brand-name medications. They are unregulated chemicals, period. The creator's hesitation about the "not for human consumption" label was the right instinct. She should have stopped there.

Bottom line on pharmacy-hopping and crowdsourcing advice

The creator is asking a real question that deserves a real answer, but her community cannot give it to her. Pharmacy quality is not something that resolves through comment section consensus. A telehealth provider who works with multiple compounding pharmacies and can verify third-party testing documentation is a more useful resource than six months of anecdotes. The frustration is valid. The methodology for solving it needs work.